IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Chan LC1,2, Li CW1, Xia W1, et al. J Clin Invest. 2019 Jul 15;130:3324-3338. doi: 10.1172/JCI126022. eCollection 2019 Jul 15.

Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. Kachuri L1,2,3, Helby J4, Bojesen SE4,5, et al. Cancer Epidemiol Biomarkers Prev. 2019 Jul;28(7):1228-1237. doi: 10.1158/1055-9965.EPI-18-1215.

IL-32γ suppresses lung cancer stem cell growth via inhibition of ITGAV-mediated STAT5 pathway. Lee YS1, Kim KC1, Mongre RK1, et al. Cell Death Dis. 2019 Jul 1;10(7):506. doi: 10.1038/s41419-019-1737-4.

Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target. Kotani N1, Yamaguchi A2, Ohnishi T2, Kuwahara R3, Nakano T1, Nakano Y1, Ida Y1, Murakoshi T1, Honke K2. Cancer Sci. 2019 Aug;110(8):2607-2619. doi: 10.1111/cas.14108. Epub 2019 Jul 23.

Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. von Itzstein MS1, Gupta A1,2, Mara KC3, Khanna S4, Gerber DE5,6,7,8. Lung. 2019 Jul 31. doi: 10.1007/s00408-019-00255-y. [Epub ahead of print]

Identifying Smoking-Related Disease on Lung Cancer Screening CT Scans: Increasing the Value. Regan EA1,2, Lowe KE1,2, Make BJ1, et al. Chronic Obstr Pulm Dis. 2019 Jul 24;6(3):233-245. doi: 10.15326/jcopdf.6.3.2018.0142.

A Geospatial Analysis of Factors Affecting Access to CT Facilities: Implications for Lung Cancer Screening. Tailor TD1, Tong BC2, Gao J3, Choudhury KR4, Rubin GD5. J Am Coll Radiol. 2019 Jul 11. pii: S1546-1440(19)30751-3. doi: 10.1016/j.jacr.2019.06.020. [Epub ahead of print]

Will That Pulmonary Nodule Become Cancerous? A Risk Prediction Model for Incident Lung Cancer. Nemesure B1, Clouston S2,3, Albano D4, Kuperberg S5, Bilfinger TV4. Cancer Prev Res (Phila). 2019 Jul;12(7):463-470. doi: 10.1158/1940-6207.CAPR-18-0500.

Optimal route planning for image-guided EBUS bronchoscopy. Zang X1, Gibbs JD2, Cheirsilp R3, Byrnes PD4, Toth J5, Bascom R5, Higgins WE6. Comput Biol Med. 2019 Jul 26;112:103361. doi: 10.1016/j.compbiomed.2019.103361. [Epub ahead of print]

Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts. Kazdal D1, Endris V2, Allgäuer M2, et al. J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30563-5. doi: 10.1016/j.jtho.2019.07.006. [Epub ahead of print]

Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study. Singhal S1, Rolfo C2, Maksymiuk AW3,4, et al. Cancers (Basel). 2019 Jul 29;11(8). pii: E1069. doi: 10.3390/cancers11081069.

Multidisciplinary approach to low-dose CT screening for lung cancer in a metropolitan community. Shields LB1, Wilkett Barnes JG2, Buckley C2, Mikos GJ2, Rogers KN2, Hamm JT2, Flynn JM2, Hester ST3, Honaker JT3. Fam Pract. 2019 Jul 4. pii: cmz036. doi: 10.1093/fampra/cmz036. [Epub ahead of print]

Prediction of Lung Cancer Screening Eligibility Using Simplified Criteria. Triplette M1,2, Donovan LM3,4, Crothers K5, Madtes DK1,5, Au DH6,4. Ann Am Thorac Soc. 2019 Jul 12. doi: 10.1513/AnnalsATS.201903-239OC. [Epub ahead of print]

Second Primary Lung Cancers Demonstrate Similar Survival with Wedge Resection and Lobectomy. Lee DS, LaChappelle C, Taioli E, Kaufman A, Wolf A, Nicastri D, Flores RM. Ann Thorac Surg. 2019 Jul 31. pii: S0003-4975(19)31064-1. doi: 10.1016/j.athoracsur.2019.06.023. [Epub ahead of print]

Uniport video assisted thoracoscopic surgery (U-VATS) exhibits increased feasibility, non-inferior tolerance, and equal efficiency compared with multiport VATS and open thoracotomy in the elderly non-small cell lung cancer patients at early stage. Zhao R1, Shi Z2, Cheng S1. Medicine (Baltimore). 2019 Jul;98(28):e16137. doi: 10.1097/MD.0000000000016137.

Evaluation of the residual lung function after thoracoscopic segmentectomy compared with lobectomy. Tane S1, Nishio W2, Nishioka Y1, Tanaka H1, Ogawa H1, Kitamura Y1, Takenaka D3, Yoshimura M1. Ann Thorac Surg. 2019 Jul 11. pii: S0003-4975(19)31005-7. doi: 10.1016/j.athoracsur.2019.05.052. [Epub ahead of print]

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. Edahiro R1, Kanazu M1, Kurebe H1, et al. PLoS One. 2019 Jul 31;14(7):e0220570. doi: 10.1371/journal.pone.0220570. eCollection 2019.

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Dagogo-Jack I1, Rooney MM1, Lin JJ2, et al. Clin Cancer Res. 2019 Jul 29. pii: clincanres.1436.2019. doi: 10.1158/1078-0432.CCR-19-1436. [Epub ahead of print]

Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA). Lenderking WR1, Lin H2, Speck RM1, Zhu Y2, Huang H2, Huang J2, Kerstein D2, Langer CJ2. Future Oncol. 2019 Jul 31. doi: 10.2217/fon-2019-0185. [Epub ahead of print]

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. Ricciuti B1, Brambilla M2, Cortellini A3, Clin Transl Oncol. 2019 Jul 22. doi: 10.1007/s12094-019-02175-y. [Epub ahead of print]

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. Ramalingam SS1, Dahlberg SE2, Belani CP3, et al. J Clin Oncol. 2019 Jul 30:JCO1901006. doi: 10.1200/JCO.19.01006. [Epub ahead of print]

Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study). Edelman MJ1, Redman MW2, Albain KS3, et al. J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557-X. doi: 10.1016/j.jtho.2019.06.027. [Epub ahead of print]

Establishment of a non-small-cell lung cancer-liver metastasis patient-derived tumor xenograft model for the evaluation of patient-tailored chemotherapy. Yang X1, Meng G2. Biosci Rep. 2019 Jul 5;39(7). pii: BSR20182082. doi: 10.1042/BSR20182082. Print 2019 Jul 31.

Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib? Tamiya M1, Tamiya A2, Suzuki H3, et al. Anticancer Res. 2019 Jul;39(7):3923-3929. doi: 10.21873/anticanres.13544.

Predictors of Respiratory Decline Following Stereotactic Ablative Radiotherapy to Multiple Lung Tumors. Moding EJ1, Liang R1, Lartey FM1, Maxim PG1, Sung A2, Diehn M3, Loo BW Jr4, Gensheimer MF5. Clin Lung Cancer. 2019 Jul 4. pii: S1525-7304(19)30142-1. doi: 10.1016/j.cllc.2019.05.015. [Epub ahead of print]

Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry. Singh R1, Ansinelli H2, Sharma D3, Jenkins J4, Davis J4, Vargo JA5, Sharma S3,6. Am J Clin Oncol. 2019 Jul;42(7):602-606. doi: 10.1097/COC.0000000000000561.

Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1-10 brain metastases treated with stereotactic radiosurgery. Nagtegaal S1, Claes A2, Suijkerbuijk K3, Schramel F4, Snijders T5, Verhoeff J2. Radiother Oncol. 2019 Jul 11;138:173-179. doi: 10.1016/j.radonc.2019.06.033. [Epub ahead of print]

Synchronous Oligometastatic Non-small Cell Lung Cancer Managed With Curative-Intent Chemoradiation Therapy: Long-term Outcomes From a Single Institution. Yegya-Raman N1, Aisner J2, Kim S3,4, Sayan M1, Li D1, Langenfeld J5, Patel M2, Malhotra J2, Jabbour SK1. Adv Radiat Oncol. 2019 Mar 22;4(3):541-550. doi: 10.1016/j.adro.2019.03.005. eCollection 2019 Jul-Sep.

Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer. Phillips I1, Sandhu S2, Lüchtenborg M3, Harden S4. Clin Oncol (R Coll Radiol). 2019 Jul 31. pii: S0936-6555(19)30293-6. doi: 10.1016/j.clon.2019.07.013. [Epub ahead of print]

Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. Shepard MJ1, Xu Z1, Donahue J2, et al. J Neurosurg. 2019 Jul 26:1-8. doi: 10.3171/2019.4.JNS19822. [Epub ahead of print]

Change in apparent diffusion coefficient is associated with local failure after stereotactic body radiation therapy for non-small cell lung cancer: a prospective clinical trial. Sampath S1, Rahmanuddin S2, Sahoo P3, Frankel P4, Boswell S5, Wong J2, Rotter A2, Rockne R3, Wong J6, Park JM7. Int J Radiat Oncol Biol Phys. 2019 Jul 1. pii: S0360-3016(19)33424-8. doi: 10.1016/j.ijrobp.2019.06.2536. [Epub ahead of print]

CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter. Qiu Z1,2, Zhu W1, Meng H1, Tong L1,3, Li X1, Luo P1, Yi L1, Zhang X1, Guo L4, Wei T1, Zhang J1. Theranostics. 2019 Jul 9;9(16):4717-4729. doi: 10.7150/thno.33680. eCollection 2019.

Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer. Araz M1, Soydal C2, Özkan E2, Sen E3, Nak D2, Kucuk ON2, Gönüllü U3, Kir KM2. Q J Nucl Med Mol Imaging. 2019 Jul 1. doi: 10.23736/S1824-4785.19.03169-8. [Epub ahead of print]

Determination of Risk Factors Related to Supraclavicular Recurrence for Limited-Stage Small Cell Lung Cancer (SCLC) Patients. Guan Y1, Zhang X1. Med Sci Monit. 2019 Jul 5;25:4968-4973. doi: 10.12659/MSM.916279.

The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score in Patients with Small Cell Lung Cancer Before First-Line Treatment with Etoposide and Progression-Free Survival. Shen XB1,2, Zhang YX1,2, Wang W2, Pan YY1,2. Med Sci Monit. 2019 Jul 29;25:5630-5639. doi: 10.12659/MSM.917968. 

Limited-Stage Small Cell Lung Cancer: Is Prophylactic Cranial Irradiation Necessary? Farris MK1, Wheless WH2, et al. Pract Radiat Oncol. 2019 Jul 1. pii: S1879-8500(19)30185-7. doi: 10.1016/j.prro.2019.06.014. [Epub ahead of print]

Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry. Singh R1, Ansinelli H2, Sharma D3, Jenkins J4, Davis J4, Vargo JA5, Sharma S3,6. Am J Clin Oncol. 2019 Jul;42(7):602-606. doi: 10.1097/COC.0000000000000561.

Heart Rate Variability and Heart Rate Recovery in Lung Cancer Survivors Eligible for Long-Term Cure. Ha D1, Malhotra A2, Ries AL2, O’Neal WT3, Fuster MM4. Respir Physiol Neurobiol. 2019 Jul 31:103264. doi: 10.1016/j.resp.2019.103264. [Epub ahead of print]

Factors Associated with Anxiety and Depression among Family Caregivers of Patients Undergoing Palliative Radiotherapy. Govina O1, Vlachou E1, Kalemikerakis I1, Papageorgiou D2, Kavga A1, Konstantinidis T3. Asia Pac J Oncol Nurs. 2019 Jul-Sep;6(3):283-291. doi: 10.4103/apjon.apjon_74_18.

The relation between psychological profiles and quality of life in patients with lung cancer. van Montfort E1, de Vries J2,3, Arts R3, Aerts JG4, Kloover JS3, Traa MJ3. Support Care Cancer. 2019 Jul 1. doi: 10.1007/s00520-019-04923-w. [Epub ahead of print]

Understanding Symptom Burden in Patients With Advanced Cancer Living in Rural Areas. Gilbertson-White S1, Perkhounkova Y1, Saeidzadeh S1, Hein M1, Dahl R1, Simons-Burnett A1. Oncol Nurs Forum. 2019 Jul 1;46(4):428-441. doi: 10.1188/19.ONF.428-441.

Retrospective Prognostic Study of Death at Home or Hospice Versus at a Hospital Among Patients With Advanced Non-Small Cell Lung Cancer. Hamamoto Y1, Ibe T1, Kodama H1, Mouri A2, Mineshita M3. Am J Hosp Palliat Care. 2019 Jul 31:1049909119865865. doi: 10.1177/1049909119865865. [Epub ahead of print]

Co-occurring Gastrointestinal Symptoms Are Associated with Taste Changes in Oncology Patients Receiving Chemotherapy. Nolden A1, Joseph PV2, Kober KM3, et al. J Pain Symptom Manage. 2019 Jul 23. pii: S0885-3924(19)30389-6. doi: 10.1016/j.jpainsymman.2019.07.016. [Epub ahead of print]

Psychological correlates of sleep quality in lung cancer patients under chemotherapy: A single-center cross-sectional study. Papadopoulos D1, Kiagia M1, Charpidou A1, Gkiozos I1, Syrigos K1. Psychooncology. 2019 Jul 2. doi: 10.1002/pon.5167. [Epub ahead of print]

The relation between psychological profiles and quality of life in patients with lung cancer. van Montfort E1, de Vries J2,3, Arts R3, Aerts JG4, Kloover JS3, Traa MJ3. Support Care Cancer. 2019 Jul 1. doi: 10.1007/s00520-019-04923-w. [Epub ahead of print]

Identification of subgroups of chemotherapy patients with distinct sleep disturbance profiles and associated co-occurring symptoms. Tejada M1, Viele C1, Kober KM1, et al. Sleep. 2019 Jul 30. pii: zsz151. doi: 10.1093/sleep/zsz151. [Epub ahead of print]

A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment. Ha D1,2, Kerr J3, Ries AL2, Fuster MM4,2, Lippman SM5, Murphy JD6. Am J Phys Med Rehabil. 2019 Jul 26. doi: 10.1097/PHM.0000000000001281. [Epub ahead of print]

“All boats will rise”: Physicians’ perspectives on multidisciplinary lung cancer care in a community-based hospital setting. Kedia SK1, Ward KD2, Collins AC2, Jackson BM3, Stewart FR3, Faris NR3, Roark KS3, Osarogiagbon RU3. Support Care Cancer. 2019 Jul 15. doi: 10.1007/s00520-019-04950-7. [Epub ahead of print]

Lung Cancer Patient and Caregiver Health Vulnerabilities and Interest in Health Promotion Interventions: An Exploratory Study. Nightingale CL1, Steffen LE1, Tooze JA2, Petty W3, Danhauer SC1, Badr H4, Weaver KE1. Glob Adv Health Med. 2019 Jul 17;8:2164956119865160. doi: 10.1177/2164956119865160. eCollection 2019.

Effects of Home-Based Exercise Training for Patients With Lung Cancer. Wang YQ1, Liu X1, Yin YY1, Ma RC1, Yang Z1, Cao HP1, Xie J1. Oncol Nurs Forum. 2019 Jul 1;46(4):E119-E134. doi: 10.1188/19.ONF.E119-E134.

Effect of Xiao-Ai-Ping injection on paclitaxel pharmacokinetics in rats by LC-MS/MS method. Shi MZ1, Xing TY2, et al. J Pharm Biomed Anal. 2019 Sep 10;174:728-733. doi: 10.1016/j.jpba.2019.07.003. Epub 2019 Jul 3.

Sex-Based Disparities Among Cancer Clinical Trial Participants. Ludmir EB1, Fuller CD1, Moningi S1, et al. J Natl Cancer Inst. 2019 Jul 27. pii: djz154. doi: 10.1093/jnci/djz154. [Epub ahead of print]

Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. Samuelsen C1, Lim J2, Golembesky A1, Shrestha S3, Wang L3, Griebsch I1. J Med Econ. 2019 Jul 17:1. doi: 10.1080/13696998.2019.1645681. [Epub ahead of print]

Association of Rurality With Survival and Guidelines-Concordant Management in Early-stage Non-Small Cell Lung Cancer. Nicoli CD1, Sprague BL2, Anker CJ3, Lester-Coll NH3. Am J Clin Oncol. 2019 Jul;42(7):607-614. doi: 10.1097/COC.0000000000000549.

Exploring Stigma Among Lung Cancer Survivors: A Scoping Literature Review. Webb LA1, McDonnell KK1, Adams SA1, Davis RE1, Felder TM1. Oncol Nurs Forum. 2019 Jul 1;46(4):402-418. doi: 10.1188/19.ONF.402-418.